Copyright
©The Author(s) 2019.
World J Gastroenterol. Jul 7, 2019; 25(25): 3218-3230
Published online Jul 7, 2019. doi: 10.3748/wjg.v25.i25.3218
Published online Jul 7, 2019. doi: 10.3748/wjg.v25.i25.3218
Table 1 Summary of clinical and demographic features for study subjects and tumor characteristics
EC | HC | χ2 | P value | |
Subjects, n | 41 | 40 | ||
Age (median, range), yr | 60, 39-77 | 59, 28-78 | ||
Sex | 6.77 | 0.12 | ||
Male | 31 | 19 | ||
Female | 10 | 21 | ||
Cancer stage | ||||
Stage I/II | 15 | - | ||
Stage III | 11 | - | ||
Stage IV | 15 | - | ||
CEA, ng/mL | ||||
Positive | 2 | - | ||
Negative | 31 | - | ||
Not measured | 8 | - | ||
CA 19-9, U/mL | ||||
Positive | 2 | - | ||
Negative | 18 | - | ||
Not measured | 21 | - | ||
Location | ||||
Cervical | 1 | - | ||
Upper thoracic | 5 | - | ||
Middle thoracic | 24 | - | ||
Lower thoracic | 11 | - | ||
Symptoms | ||||
Dysphagia | 40 | - | ||
Gastroesophageal reflux | 27 | - |
Table 2 Potential urine biomarkers for discriminating esophageal cancer patients from healthy controls
Metabolite | Chemicalshift, ppm | Fold difference | AUC (95%CI) | Related metabolic pathways | |
EC / HC | P value | ||||
Acetoacetate | 2.25–2.28 | 1.55 ↑ | < 0.001 | 0.745 (0.636–0.836) | Fatty acid metabolism, TCA cycle |
Glutamate | 2.04–2.06 | 1.22 ↑ | 0.002 | 0.702 (0.590–0.798) | Glutaminolysis, TCA cycle |
Cis-aconitate | 3.40–3.46 | 1.30 ↑ | 0.001 | 0.719 (0.608–0.813) | TCA cycle, glyoxylate and dicarboxylate metabolism |
Citrate | 2.48–2.54 2.64–2.66 | 1.27 ↑ | 0.002 | 0.643 (0.528–0.746) | TCA cycle |
Hippurate | 7.51–7.56 7.60–7.65 7.78–7.84 | 0.45 ↓ | 0.002 | 0.702 (0.591–0.799) | Gut microflora metabolism |
Ethanola-mine | 3.08–3.16 | 0.86 ↓ | 0.001 | 0.723 (0.613–0.817) | Fatty acid metabolism |
Glycine | 3.54–3.55 | 0.85 ↓ | 0.003 | 0.633 (0.518–0.737) | Amino acid metabolism |
Creatinine | 3.03–3.06 4.05–4.10 | 0.95 ↓ | < 0.001 | 0.790 (0.685–0.872) | Urea metabolism, Creatinine metabolism |
Taurine | 3.26–3.28 | 0.53 ↓ | < 0.001 | 0.763 (0.655–0.850) | Amino acid metabolism |
Glucose | 3.73–3.80 | 0.89 ↓ | 0.007 | 0.694 (0.581–0.792) | Glycolysis; TCA cycle |
Table 3 Potential tissue biomarkers for discriminating esophageal cancer tissue from adjacent noncancerous tissue
Metabolite | Chemicalshift, ppm | Fold difference | AUC (95%CI) | Related metabolic pathways | |
ECT / ANT | P value | ||||
Valine | 0.96–0.99 1.02–1.04 | 1.63 ↑ | < 0.001 | 0.988 (0.889-1.000) | Amino acid metabolism |
Leucine | 0.93–0.95 | 1.32 ↑ | < 0.001 | 0.852 (0.705-0.944) | Amino acid metabolism |
Glutamate | 1.97–2.08 2.32–2.39 | 1.30 ↑ | < 0.001 | 0.930 (0.803-0.986) | Glutaminolysis, TCA cycle |
Acetate | 1.88–1.93 | 1.33 ↑ | 0.001 | 0.790 (0.632-0.902) | SCFA metabolism |
Alanine | 1.43–1.48 | 1.44 ↑ | < 0.001 | 0.920 (0.789-0.982) | Amino acid metabolism, Gluconeogenesis |
Choline | 3.19–3.22 | 1.59 ↑ | < 0.001 | 0.980 (0.876-1.000) | Choline metabolism, Lipid metabolism |
Succinate | 2.39–2.40 | 2.12 ↑ | 0.009 | 0.738 (0.575-0.864) | TCA cycle |
Citrate | 2.68–2.71 | 1.42 ↑ | < 0.001 | 0.942 (0.820-0.991) | TCA cycle |
Glucose | 3.37–3.44 3.50–3.52 | 0.72 ↓ | < 0.001 | 0.928 (0.800-0.985) | Glycolysis, TCA cycle |
Creatinine | 3.02–3.03 4.04–4.06 | 0.64 ↓ | < 0.001 | 0.963 (0.849-0.997) | Urea metabolism, Creatine metabolism |
Glycine | 3.52–3.55 | 0.75 ↓ | < 0.001 | 0.850 (0.702-0.943) | Amino acid metabolism |
Threonine | 3.58–3.62 | 0.60 ↓ | < 0.001 | 0.933 (0.806-0.987) | Amino acid metabolism |
Creatine | 3.90–3.94 | 0.78 ↓ | < 0.001 | 0.917 (0.786-0.981) | Urea metabolism, Creatine metabolism |
Glutamine | 2.42–2.48 | 0.77 ↓ | < 0.001 | 0.895 (0.757-0.969) | Glutaminolysis, TCA cycle |
Taurine | 3.24–3.28 3.33–3.34 | 0.78 ↓ | < 0.001 | 0.878 (0.735-0.960) | Amino acid metabolism |
- Citation: Liang JH, Lin Y, Ouyang T, Tang W, Huang Y, Ye W, Zhao JY, Wang ZN, Ma CC. Nuclear magnetic resonance-based metabolomics and metabolic pathway networks from patient-matched esophageal carcinoma, adjacent noncancerous tissues and urine. World J Gastroenterol 2019; 25(25): 3218-3230
- URL: https://www.wjgnet.com/1007-9327/full/v25/i25/3218.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i25.3218